Infectious Disease Research Institute

Glaxosmithkline Biologicals Sa

Corixa Corporation

Access To Advanced Health Institute

Rhea N Coler

Steven G Reed

Gregory C Ireton

Sylvie Bertholet

Davin C Dillon

Antonio Campos-Neto

Peter Probst

Ajay Bhatia

Yves Lobet

John R Webb

Yasir A W Skeiky

Yasir A Skeiky

Martine Marchand

Mark Brannon

The present invention relates to compositions and fusion proteins containing at least twosp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.

Immunogenic compositions comprisingpolypeptides and fusions thereof

The present invention relates to compositions and fusion proteins containing at least twosp.) antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.

The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an activeinfection or an active infection resulting from reactivation of a latent infection in a mammal and to methods of improving the efficacy of chemotherapy regimens against activeinfection.

Compositions and methods for treating an activeinfection

The present invention relates to compositions and fusion proteins containing at least twosp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis ofinfections.

[object Object]

The present invention is directed to methods of preventing reactivation of active and latentinfections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against ainfection. The methods also provide for shortening the time course of a chemotherapeutic regimen against ainfection.

The present invention relates to compositions and fusion proteins containing at least twosp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis ofinfection.

Compositions and methods for preventing, treating and detecting leishmaniasis and stimulating immune responses in patients are disclosed. The compounds provided include polypeptides that contain at least an immunogenic portion of one or more Leishmania antigens, or a variant thereof. Vaccines and pharmaceutical compositions comprising such polypeptides, or polynucleotides encoding such polypeptides, are also provided and may be used, for example, for the prevention and therapy of leishmaniasis, as well as for the detection of Leishmania infection.

Growing community of inventors

Seattle, WA, United States of America

Rhea N Coler